# Tafenoquine and ACTs (TADORE- Plus)

> **NCT07060794** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Menzies School of Health Research** · enrollment: 507 (estimated)

## Conditions studied

- Vivax Malaria

## Interventions

- **DRUG:** Tafenoquine plus DHA-Piperaquine
- **DRUG:** Tafenoquine plus Artesunate-pyronaridine

## Key facts

- **NCT ID:** NCT07060794
- **Lead sponsor:** Menzies School of Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 507 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07060794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07060794, "Tafenoquine and ACTs (TADORE- Plus)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07060794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*